Global Burden of Thyroid Cancer From 1990 to 2017
Thyroid cancer is the most pervasive endocrine cancer worldwide. Studies examining the association between thyroid cancer and country, sex, age, sociodemographic index (SDI), and other factors are lacking. To examine the thyroid cancer burden and variation trends at the global, regional, and nationa...
Saved in:
| Published in | JAMA health forum Vol. 3; no. 6; p. e208759 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
American Medical Association
26.06.2020
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Thyroid cancer is the most pervasive endocrine cancer worldwide. Studies examining the association between thyroid cancer and country, sex, age, sociodemographic index (SDI), and other factors are lacking.
To examine the thyroid cancer burden and variation trends at the global, regional, and national levels using data on sex, age, and SDI.
In this cross-sectional study, epidemiologic data were gathered using the Global Health Data Exchange query tool, covering persons of all ages with thyroid cancer in 195 countries and 21 regions from January 1, 1990, to December 31, 2017; data analysis was completed on October 1, 2019. All participants met the Global Burden of Disease Study inclusion criteria.
Outcomes included incidence, deaths, and disability-adjusted life-years (DALYs) of thyroid cancer. Measures were stratified by sex, region, country, age, and SDI. The estimated annual percentage changes (EAPCs) and age-standardized rates were calculated to evaluate the temporal trends.
Increases of thyroid cancer were noted in incident cases (169%), deaths (87%), and DALYs (75%). Age-standardized incidence rate (ASIR) showed an upward trend over time, with an EAPC of 1.59 (95% CI, 1.51-1.67); decreases were noted in EAPCs of age-standardized death rate (-0.15; 95% CI, -0.19 to -0.12) and age-standardized DALY rate (-0.11; 95% CI, -0.15 to -0.08). Almost half (41.73% for incidence, 50.92% for deaths, and 54.39% for DALYs) of the thyroid cancer burden was noted in Southern and Eastern Asia. In addition, females accounted for most of the thyroid cancer burden (70.22% for incidence, 58.39% for deaths, and 58.68% for DALYs) and increased by years in this population, although the ASIR of males with thyroid cancer (EAPC, 2.18; 95% CI, 2.07-2.28) increased faster than that of females (EAPC, 1.38; 95% CI, 1.30-1.46). A third (34%) of patients with thyroid cancer resided in countries with a high SDI, and most patients were aged 50 to 69 years, which was older than the age in other quintiles (high SDI quintile compared with all other quintiles, P<.05). The most common age at onset of thyroid cancer worldwide was 15 to 49 years in female individuals compared with 50 to 69 years in male individuals (P<.05). Death from thyroid cancer was concentrated in participants aged 70 years or older and increased by years (average annual percentage change, 0.10; 95% CI, 0.01-0.21; P<.05). Furthermore, people in lower SDI quintiles developed thyroid cancer and died from it earlier than those in other quintiles (high and high-middle SDI vs low and low-middle SDI, P<.05).
Data from this study suggest considerable heterogeneity in the epidemiologic patterns of thyroid cancer across sex, age, SDI, region, and country, providing information for governments that may help improve national and local cancer control policies. |
|---|---|
| AbstractList | This cross-sectional study examines the worldwide temporal trends of thyroid cancer according to geographic location, sex, age, and socioeconomic index. Importance Thyroid cancer is the most pervasive endocrine cancer worldwide. Studies examining the association between thyroid cancer and country, sex, age, sociodemographic index (SDI), and other factors are lacking. Objective To examine the thyroid cancer burden and variation trends at the global, regional, and national levels using data on sex, age, and SDI. Design, Setting, and Participants In this cross-sectional study, epidemiologic data were gathered using the Global Health Data Exchange query tool, covering persons of all ages with thyroid cancer in 195 countries and 21 regions from January 1, 1990, to December 31, 2017; data analysis was completed on October 1, 2019. All participants met the Global Burden of Disease Study inclusion criteria. Main Outcomes and Measures Outcomes included incidence, deaths, and disability-adjusted life-years (DALYs) of thyroid cancer. Measures were stratified by sex, region, country, age, and SDI. The estimated annual percentage changes (EAPCs) and age-standardized rates were calculated to evaluate the temporal trends. Results Increases of thyroid cancer were noted in incident cases (169%), deaths (87%), and DALYs (75%). Age-standardized incidence rate (ASIR) showed an upward trend over time, with an EAPC of 1.59 (95% CI, 1.51-1.67); decreases were noted in EAPCs of age-standardized death rate (−0.15; 95% CI, −0.19 to −0.12) and age-standardized DALY rate (−0.11; 95% CI, −0.15 to −0.08). Almost half (41.73% for incidence, 50.92% for deaths, and 54.39% for DALYs) of the thyroid cancer burden was noted in Southern and Eastern Asia. In addition, females accounted for most of the thyroid cancer burden (70.22% for incidence, 58.39% for deaths, and 58.68% for DALYs) and increased by years in this population, although the ASIR of males with thyroid cancer (EAPC, 2.18; 95% CI, 2.07-2.28) increased faster than that of females (EAPC, 1.38; 95% CI, 1.30-1.46). A third (34%) of patients with thyroid cancer resided in countries with a high SDI, and most patients were aged 50 to 69 years, which was older than the age in other quintiles (high SDI quintile compared with all other quintiles,P<.05). The most common age at onset of thyroid cancer worldwide was 15 to 49 years in female individuals compared with 50 to 69 years in male individuals (P<.05). Death from thyroid cancer was concentrated in participants aged 70 years or older and increased by years (average annual percentage change, 0.10; 95% CI, 0.01-0.21;P<.05). Furthermore, people in lower SDI quintiles developed thyroid cancer and died from it earlier than those in other quintiles (high and high-middle SDI vs low and low-middle SDI,P<.05). Conclusions and Relevance Data from this study suggest considerable heterogeneity in the epidemiologic patterns of thyroid cancer across sex, age, SDI, region, and country, providing information for governments that may help improve national and local cancer control policies. Thyroid cancer is the most pervasive endocrine cancer worldwide. Studies examining the association between thyroid cancer and country, sex, age, sociodemographic index (SDI), and other factors are lacking.ImportanceThyroid cancer is the most pervasive endocrine cancer worldwide. Studies examining the association between thyroid cancer and country, sex, age, sociodemographic index (SDI), and other factors are lacking.To examine the thyroid cancer burden and variation trends at the global, regional, and national levels using data on sex, age, and SDI.ObjectiveTo examine the thyroid cancer burden and variation trends at the global, regional, and national levels using data on sex, age, and SDI.In this cross-sectional study, epidemiologic data were gathered using the Global Health Data Exchange query tool, covering persons of all ages with thyroid cancer in 195 countries and 21 regions from January 1, 1990, to December 31, 2017; data analysis was completed on October 1, 2019. All participants met the Global Burden of Disease Study inclusion criteria.Design, Setting, and ParticipantsIn this cross-sectional study, epidemiologic data were gathered using the Global Health Data Exchange query tool, covering persons of all ages with thyroid cancer in 195 countries and 21 regions from January 1, 1990, to December 31, 2017; data analysis was completed on October 1, 2019. All participants met the Global Burden of Disease Study inclusion criteria.Outcomes included incidence, deaths, and disability-adjusted life-years (DALYs) of thyroid cancer. Measures were stratified by sex, region, country, age, and SDI. The estimated annual percentage changes (EAPCs) and age-standardized rates were calculated to evaluate the temporal trends.Main Outcomes and MeasuresOutcomes included incidence, deaths, and disability-adjusted life-years (DALYs) of thyroid cancer. Measures were stratified by sex, region, country, age, and SDI. The estimated annual percentage changes (EAPCs) and age-standardized rates were calculated to evaluate the temporal trends.Increases of thyroid cancer were noted in incident cases (169%), deaths (87%), and DALYs (75%). Age-standardized incidence rate (ASIR) showed an upward trend over time, with an EAPC of 1.59 (95% CI, 1.51-1.67); decreases were noted in EAPCs of age-standardized death rate (-0.15; 95% CI, -0.19 to -0.12) and age-standardized DALY rate (-0.11; 95% CI, -0.15 to -0.08). Almost half (41.73% for incidence, 50.92% for deaths, and 54.39% for DALYs) of the thyroid cancer burden was noted in Southern and Eastern Asia. In addition, females accounted for most of the thyroid cancer burden (70.22% for incidence, 58.39% for deaths, and 58.68% for DALYs) and increased by years in this population, although the ASIR of males with thyroid cancer (EAPC, 2.18; 95% CI, 2.07-2.28) increased faster than that of females (EAPC, 1.38; 95% CI, 1.30-1.46). A third (34%) of patients with thyroid cancer resided in countries with a high SDI, and most patients were aged 50 to 69 years, which was older than the age in other quintiles (high SDI quintile compared with all other quintiles, P<.05). The most common age at onset of thyroid cancer worldwide was 15 to 49 years in female individuals compared with 50 to 69 years in male individuals (P<.05). Death from thyroid cancer was concentrated in participants aged 70 years or older and increased by years (average annual percentage change, 0.10; 95% CI, 0.01-0.21; P<.05). Furthermore, people in lower SDI quintiles developed thyroid cancer and died from it earlier than those in other quintiles (high and high-middle SDI vs low and low-middle SDI, P<.05).ResultsIncreases of thyroid cancer were noted in incident cases (169%), deaths (87%), and DALYs (75%). Age-standardized incidence rate (ASIR) showed an upward trend over time, with an EAPC of 1.59 (95% CI, 1.51-1.67); decreases were noted in EAPCs of age-standardized death rate (-0.15; 95% CI, -0.19 to -0.12) and age-standardized DALY rate (-0.11; 95% CI, -0.15 to -0.08). Almost half (41.73% for incidence, 50.92% for deaths, and 54.39% for DALYs) of the thyroid cancer burden was noted in Southern and Eastern Asia. In addition, females accounted for most of the thyroid cancer burden (70.22% for incidence, 58.39% for deaths, and 58.68% for DALYs) and increased by years in this population, although the ASIR of males with thyroid cancer (EAPC, 2.18; 95% CI, 2.07-2.28) increased faster than that of females (EAPC, 1.38; 95% CI, 1.30-1.46). A third (34%) of patients with thyroid cancer resided in countries with a high SDI, and most patients were aged 50 to 69 years, which was older than the age in other quintiles (high SDI quintile compared with all other quintiles, P<.05). The most common age at onset of thyroid cancer worldwide was 15 to 49 years in female individuals compared with 50 to 69 years in male individuals (P<.05). Death from thyroid cancer was concentrated in participants aged 70 years or older and increased by years (average annual percentage change, 0.10; 95% CI, 0.01-0.21; P<.05). Furthermore, people in lower SDI quintiles developed thyroid cancer and died from it earlier than those in other quintiles (high and high-middle SDI vs low and low-middle SDI, P<.05).Data from this study suggest considerable heterogeneity in the epidemiologic patterns of thyroid cancer across sex, age, SDI, region, and country, providing information for governments that may help improve national and local cancer control policies.Conclusions and RelevanceData from this study suggest considerable heterogeneity in the epidemiologic patterns of thyroid cancer across sex, age, SDI, region, and country, providing information for governments that may help improve national and local cancer control policies. Thyroid cancer is the most pervasive endocrine cancer worldwide. Studies examining the association between thyroid cancer and country, sex, age, sociodemographic index (SDI), and other factors are lacking. To examine the thyroid cancer burden and variation trends at the global, regional, and national levels using data on sex, age, and SDI. In this cross-sectional study, epidemiologic data were gathered using the Global Health Data Exchange query tool, covering persons of all ages with thyroid cancer in 195 countries and 21 regions from January 1, 1990, to December 31, 2017; data analysis was completed on October 1, 2019. All participants met the Global Burden of Disease Study inclusion criteria. Outcomes included incidence, deaths, and disability-adjusted life-years (DALYs) of thyroid cancer. Measures were stratified by sex, region, country, age, and SDI. The estimated annual percentage changes (EAPCs) and age-standardized rates were calculated to evaluate the temporal trends. Increases of thyroid cancer were noted in incident cases (169%), deaths (87%), and DALYs (75%). Age-standardized incidence rate (ASIR) showed an upward trend over time, with an EAPC of 1.59 (95% CI, 1.51-1.67); decreases were noted in EAPCs of age-standardized death rate (-0.15; 95% CI, -0.19 to -0.12) and age-standardized DALY rate (-0.11; 95% CI, -0.15 to -0.08). Almost half (41.73% for incidence, 50.92% for deaths, and 54.39% for DALYs) of the thyroid cancer burden was noted in Southern and Eastern Asia. In addition, females accounted for most of the thyroid cancer burden (70.22% for incidence, 58.39% for deaths, and 58.68% for DALYs) and increased by years in this population, although the ASIR of males with thyroid cancer (EAPC, 2.18; 95% CI, 2.07-2.28) increased faster than that of females (EAPC, 1.38; 95% CI, 1.30-1.46). A third (34%) of patients with thyroid cancer resided in countries with a high SDI, and most patients were aged 50 to 69 years, which was older than the age in other quintiles (high SDI quintile compared with all other quintiles, P<.05). The most common age at onset of thyroid cancer worldwide was 15 to 49 years in female individuals compared with 50 to 69 years in male individuals (P<.05). Death from thyroid cancer was concentrated in participants aged 70 years or older and increased by years (average annual percentage change, 0.10; 95% CI, 0.01-0.21; P<.05). Furthermore, people in lower SDI quintiles developed thyroid cancer and died from it earlier than those in other quintiles (high and high-middle SDI vs low and low-middle SDI, P<.05). Data from this study suggest considerable heterogeneity in the epidemiologic patterns of thyroid cancer across sex, age, SDI, region, and country, providing information for governments that may help improve national and local cancer control policies. |
| Author | Zhai, Zhen Xu, Peng Li, HongTao Deng, YuJiao Li, Na Lyu, Jun Wang, Meng Hao, Qian Yang, Si Tian, Tian Dai, ZhiJun Jin, TianBo Wu, Ying Zhou, LingHui Song, DingLi |
| AuthorAffiliation | 2 Department of Oncology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China 4 Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, School of Life Sciences, Northwest University, Xi’an, China 1 Department of Breast Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China 5 Department of Clinical Research, The First Affiliated Hospital of Jinan University, Guangzhou, China 3 Department of Breast, Head and Neck Surgery, The Third Affiliated Teaching Hospital of Xinjiang Medical University (Affiliated Tumor Hospital), Urumqi, China |
| AuthorAffiliation_xml | – name: 5 Department of Clinical Research, The First Affiliated Hospital of Jinan University, Guangzhou, China – name: 2 Department of Oncology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China – name: 3 Department of Breast, Head and Neck Surgery, The Third Affiliated Teaching Hospital of Xinjiang Medical University (Affiliated Tumor Hospital), Urumqi, China – name: 1 Department of Breast Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China – name: 4 Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, School of Life Sciences, Northwest University, Xi’an, China |
| Author_xml | – sequence: 1 givenname: YuJiao surname: Deng fullname: Deng, YuJiao organization: Department of Breast Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China, Department of Oncology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China – sequence: 2 givenname: HongTao surname: Li fullname: Li, HongTao organization: Department of Breast, Head and Neck Surgery, The Third Affiliated Teaching Hospital of Xinjiang Medical University (Affiliated Tumor Hospital), Urumqi, China – sequence: 3 givenname: Meng surname: Wang fullname: Wang, Meng organization: Department of Oncology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China – sequence: 4 givenname: Na surname: Li fullname: Li, Na organization: Department of Breast Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China, Department of Oncology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China – sequence: 5 givenname: Tian surname: Tian fullname: Tian, Tian organization: Department of Oncology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China – sequence: 6 givenname: Ying surname: Wu fullname: Wu, Ying organization: Department of Oncology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China – sequence: 7 givenname: Peng surname: Xu fullname: Xu, Peng organization: Department of Oncology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China – sequence: 8 givenname: Si surname: Yang fullname: Yang, Si organization: Department of Breast Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China, Department of Oncology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China – sequence: 9 givenname: Zhen surname: Zhai fullname: Zhai, Zhen organization: Department of Oncology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China – sequence: 10 givenname: LingHui surname: Zhou fullname: Zhou, LingHui organization: Department of Oncology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China – sequence: 11 givenname: Qian surname: Hao fullname: Hao, Qian organization: Department of Oncology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China – sequence: 12 givenname: DingLi surname: Song fullname: Song, DingLi organization: Department of Oncology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China – sequence: 13 givenname: TianBo surname: Jin fullname: Jin, TianBo organization: Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, School of Life Sciences, Northwest University, Xi’an, China – sequence: 14 givenname: Jun surname: Lyu fullname: Lyu, Jun organization: Department of Clinical Research, The First Affiliated Hospital of Jinan University, Guangzhou, China – sequence: 15 givenname: ZhiJun surname: Dai fullname: Dai, ZhiJun organization: Department of Breast Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32589231$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkUtPAjEUhRuDEUT-ghnjxg3Yx_S10SgRNDFxg-umM9ORwZkWOzMa_r0lgEEWuupN-t1z77nnFHSsswaACwRHCEJ0vdCVtqb5cv7dLY0dYYjhSHAqj0APUx4PiYC0s1d3waCuFxAGDhHJ6AnoEkyFxAT1AJqWLtFldN_6zNjI5dFsvvKuyKKxtqnx0cS7KkJSwqhxUVDgZ-A412VtBtu3D14nD7Px4_D5Zfo0vnseasriZohJbpI8SRHjKM4zyjKIciE15lAII2ODac6gJEJrESMdU8y4TgxnjKZZRhPSBzcb3WWbVCZLjW28LtXSF5X2K-V0oX7_2GKu3tyn4gRDEqz2wdVWwLuP1tSNqoo6NWUZzufaWuEYCUSIlCKglwfowrXeBnsKM4Ego5STvynGJUZcskCd7-_9s_Du5gG43QCpd3XtTa7SotFN4dY2ilIhqNZBq4Og1TpotQ46KMgDhd2Q_3u_AZ37sJA |
| CitedBy_id | crossref_primary_10_1016_j_prp_2024_155238 crossref_primary_10_1089_jwh_2023_0947 crossref_primary_10_1016_j_clnesp_2021_11_026 crossref_primary_10_3390_ijms242216334 crossref_primary_10_1186_s13044_023_00173_5 crossref_primary_10_1186_s13044_024_00213_8 crossref_primary_10_1016_j_biopha_2024_116840 crossref_primary_10_1186_s40364_021_00310_y crossref_primary_10_18231_j_ijpo_2024_029 crossref_primary_10_1210_clinem_dgad571 crossref_primary_10_1166_mex_2024_2692 crossref_primary_10_7189_jogh_14_04084 crossref_primary_10_1210_jendso_bvaa178 crossref_primary_10_1186_s12940_024_01143_6 crossref_primary_10_3390_diagnostics12112716 crossref_primary_10_3233_CBM_230566 crossref_primary_10_1016_j_oraloncology_2023_106391 crossref_primary_10_1007_s11306_024_02119_w crossref_primary_10_3390_ijerph21030324 crossref_primary_10_1186_s12957_024_03455_w crossref_primary_10_3389_fmolb_2022_925389 crossref_primary_10_3390_biomedicines10071554 crossref_primary_10_1016_j_ecoenv_2024_116139 crossref_primary_10_1186_s12891_024_07250_2 crossref_primary_10_1016_j_drup_2023_100939 crossref_primary_10_1111_cas_15909 crossref_primary_10_1038_s41598_022_17115_0 crossref_primary_10_3390_ijms24043586 crossref_primary_10_1007_s00432_025_06098_w crossref_primary_10_3390_biomedicines11020298 crossref_primary_10_17816_pmj421112_118 crossref_primary_10_1186_s12902_021_00871_x crossref_primary_10_18632_aging_204037 crossref_primary_10_1007_s12149_023_01826_z crossref_primary_10_1016_j_nut_2022_111840 crossref_primary_10_3389_fendo_2023_1113977 crossref_primary_10_1016_j_amjms_2022_08_005 crossref_primary_10_1111_jgh_16572 crossref_primary_10_1089_thy_2021_0131 crossref_primary_10_3390_ijms22116033 crossref_primary_10_3390_life14070809 crossref_primary_10_1177_01455613241228078 crossref_primary_10_1089_ten_tea_2021_0221 crossref_primary_10_3389_fendo_2024_1343002 crossref_primary_10_1016_j_chemosphere_2023_140581 crossref_primary_10_3390_cancers14071782 crossref_primary_10_3389_fnut_2024_1384023 crossref_primary_10_3390_cancers13153792 crossref_primary_10_1007_s11356_022_24410_w crossref_primary_10_3390_life14060696 crossref_primary_10_1186_s13046_023_02751_9 crossref_primary_10_1210_clinem_dgad580 crossref_primary_10_3390_diseases11010009 crossref_primary_10_1016_j_asjsur_2024_11_212 crossref_primary_10_3390_ijerph191610068 crossref_primary_10_7759_cureus_38989 crossref_primary_10_1111_cen_15119 crossref_primary_10_4103_sjoh_sjoh_39_23 crossref_primary_10_1038_s41597_023_02253_5 crossref_primary_10_3390_ijms251910701 crossref_primary_10_1021_acsnano_4c05700 crossref_primary_10_3390_molecules28093705 crossref_primary_10_3389_fpubh_2024_1371253 crossref_primary_10_1186_s12957_025_03670_z crossref_primary_10_1016_j_mce_2021_111491 crossref_primary_10_1016_j_knosys_2023_110721 crossref_primary_10_1002_mog2_70008 crossref_primary_10_3389_fendo_2023_1152514 crossref_primary_10_3389_fnut_2024_1494574 crossref_primary_10_1186_s12905_025_03547_z crossref_primary_10_1515_med_2023_0660 crossref_primary_10_3389_fendo_2023_1110038 crossref_primary_10_1007_s11356_022_22407_z crossref_primary_10_3390_joma1010007 crossref_primary_10_1016_j_nurpra_2024_105204 crossref_primary_10_1186_s12885_024_12176_y crossref_primary_10_3389_fneur_2021_759221 crossref_primary_10_2196_54891 crossref_primary_10_1007_s12020_021_02717_x crossref_primary_10_1016_j_heliyon_2023_e23964 crossref_primary_10_1002_cam4_3970 crossref_primary_10_1186_s12885_023_11361_9 crossref_primary_10_1016_j_crphar_2022_100131 crossref_primary_10_1080_21655979_2022_2047400 crossref_primary_10_12998_wjcc_v10_i12_3709 crossref_primary_10_3389_fendo_2021_672350 crossref_primary_10_1109_ACCESS_2024_3418974 crossref_primary_10_1080_01635581_2022_2115082 crossref_primary_10_1186_s12889_021_10635_w crossref_primary_10_3389_fneur_2023_1307413 crossref_primary_10_21272_eumj_2022_10_4__322_332 crossref_primary_10_1016_j_nantod_2025_102694 crossref_primary_10_1016_j_fmre_2023_01_008 crossref_primary_10_3389_fendo_2021_738213 crossref_primary_10_3389_fonc_2023_1181325 crossref_primary_10_30841_2708_8731_1_2022_258143 crossref_primary_10_1016_j_anl_2024_04_008 crossref_primary_10_3390_cancers13143436 crossref_primary_10_3892_ol_2021_12934 crossref_primary_10_3389_fimmu_2024_1478395 crossref_primary_10_1001_jamaoncol_2023_1379 crossref_primary_10_1155_2022_3534783 crossref_primary_10_4103_mj_mj_46_22 crossref_primary_10_1007_s00405_023_07992_0 crossref_primary_10_3389_fonc_2023_1231636 crossref_primary_10_1136_ip_2023_044915 crossref_primary_10_1080_07853890_2023_2232372 crossref_primary_10_1007_s12020_021_02698_x crossref_primary_10_1016_j_sbsr_2024_100660 crossref_primary_10_2147_RMHP_S424052 crossref_primary_10_3389_fonc_2021_756246 crossref_primary_10_1155_2022_5821545 crossref_primary_10_3389_fonc_2024_1447903 crossref_primary_10_3390_diagnostics11050907 crossref_primary_10_1007_s40618_021_01584_7 crossref_primary_10_1038_s41598_021_96637_5 crossref_primary_10_2217_fon_2022_1297 crossref_primary_10_1016_j_cpet_2023_12_001 crossref_primary_10_1016_j_ultrasmedbio_2023_03_019 crossref_primary_10_1007_s12020_022_03274_7 crossref_primary_10_3390_endocrines3040065 crossref_primary_10_1186_s13044_021_00106_0 crossref_primary_10_1038_s41598_023_49123_z crossref_primary_10_3389_fonc_2024_1412243 crossref_primary_10_1038_s41420_024_02157_2 crossref_primary_10_1111_ene_70031 crossref_primary_10_7189_jogh_14_04131 crossref_primary_10_1093_joccuh_uiae040 crossref_primary_10_1007_s12020_024_04068_9 crossref_primary_10_3390_cancers15184502 crossref_primary_10_1007_s00104_022_01726_4 crossref_primary_10_3389_fonc_2022_955358 crossref_primary_10_1002_kjm2_12621 crossref_primary_10_1007_s42000_023_00517_8 crossref_primary_10_1016_j_ejim_2023_06_005 crossref_primary_10_1016_j_scitotenv_2023_161975 crossref_primary_10_1186_s13075_021_02705_6 crossref_primary_10_1007_s13193_021_01429_y crossref_primary_10_1097_MD_0000000000037655 crossref_primary_10_1007_s40200_025_01581_0 crossref_primary_10_3389_fendo_2022_893461 crossref_primary_10_1093_glycob_cwad037 crossref_primary_10_1002_cam4_3823 crossref_primary_10_1016_j_asjsur_2024_02_125 crossref_primary_10_1016_j_phyplu_2021_100108 crossref_primary_10_1007_s11356_024_32031_8 crossref_primary_10_1007_s13193_024_02021_w crossref_primary_10_1155_2022_7841219 crossref_primary_10_1186_s12902_023_01332_3 crossref_primary_10_3389_fendo_2023_1256232 crossref_primary_10_2478_raon_2024_0040 crossref_primary_10_16956_jes_2024_24_3_61 crossref_primary_10_1186_s12885_025_13847_0 crossref_primary_10_3389_fonc_2021_769807 crossref_primary_10_7189_jogh_13_04108 crossref_primary_10_1002_ijc_33889 crossref_primary_10_1097_CCO_0000000000001103 crossref_primary_10_3389_fendo_2021_707233 crossref_primary_10_3389_fendo_2023_1099449 crossref_primary_10_1097_CCO_0000000000001104 crossref_primary_10_2147_DDDT_S409617 crossref_primary_10_3390_ijerph19095399 crossref_primary_10_3390_systems11100519 crossref_primary_10_1016_j_heliyon_2023_e22490 crossref_primary_10_3389_fphar_2022_928419 crossref_primary_10_1016_j_sipas_2023_100176 crossref_primary_10_1038_s41416_024_02575_0 crossref_primary_10_17816_onco105514 crossref_primary_10_1007_s10653_021_01133_4 crossref_primary_10_3389_fendo_2022_1038041 crossref_primary_10_3389_fpubh_2021_729684 crossref_primary_10_3389_fonc_2024_1330030 crossref_primary_10_1002_ijc_33537 crossref_primary_10_3389_fendo_2022_1026737 crossref_primary_10_1089_thy_2022_0155 crossref_primary_10_1016_j_envres_2023_116309 crossref_primary_10_1007_s11042_024_18985_4 crossref_primary_10_3389_fendo_2024_1462251 crossref_primary_10_3892_mmr_2022_12636 crossref_primary_10_1186_s12889_023_15539_5 crossref_primary_10_3803_EnM_2023_1723 crossref_primary_10_1186_s13044_024_00197_5 crossref_primary_10_3389_fendo_2022_909333 crossref_primary_10_1111_1759_7714_14099 crossref_primary_10_1177_20420188221090012 crossref_primary_10_3389_fpubh_2022_1018866 crossref_primary_10_31083_j_fbl2703101 crossref_primary_10_1002_ctm2_70172 crossref_primary_10_3389_fmed_2021_635771 crossref_primary_10_1186_s12864_021_07895_6 crossref_primary_10_3389_fped_2022_972809 crossref_primary_10_1016_j_envint_2021_106725 crossref_primary_10_1001_jamanetworkopen_2021_44198 crossref_primary_10_1016_j_identj_2024_04_020 crossref_primary_10_1016_j_etap_2024_104387 crossref_primary_10_1007_s11010_022_04606_x crossref_primary_10_31083_j_fbl2801017 crossref_primary_10_1080_1354750X_2024_2445258 crossref_primary_10_1016_j_heliyon_2024_e39401 crossref_primary_10_3389_fendo_2024_1500926 crossref_primary_10_3390_app11041670 crossref_primary_10_2147_PGPM_S352225 crossref_primary_10_3389_fendo_2024_1498797 crossref_primary_10_3389_fendo_2022_904437 crossref_primary_10_1089_thy_2021_0602 crossref_primary_10_1007_s11604_023_01517_9 crossref_primary_10_1007_s00520_023_08049_y crossref_primary_10_3389_fneur_2023_1241158 crossref_primary_10_1007_s11517_023_02849_4 crossref_primary_10_1002_agm2_12277 crossref_primary_10_36740_WLek202211227 |
| Cites_doi | 10.1111/cen.2016.84.issue-2 10.1016/S0140-6736(16)30388-9 10.1007/s10552-008-9219-5 10.1016/S0140-6736(14)62242-X 10.5041/RMMJ.10228 10.1016/S0140-6736(14)60909-0 10.1089/thy.2013.0045 10.2217/fon.10.127 10.1089/thy.2013.0367 10.1089/thy.2006.16.1033 10.1038/nrendo.2016.110 10.1016/0002-9343(94)90321-2 10.1186/1471-2407-6-284 10.1158/1055-9965.EPI-08-0976 10.1093/jnci/djv345 10.1089/thy.2012.0269 10.1056/NEJMc1507622 10.1016/S0140-6736(16)30172-6 10.1016/j.canep.2015.04.015 10.1016/j.canep.2013.03.015 10.1056/NEJMp1604412 10.1177/1010539512436874 10.3322/caac.v68.6 10.1089/thy.2016.0075 10.1126/science.1250542 10.1089/thy.2015.0020 10.1136/bmj.j377 10.1017/S0022215116009737 10.1089/thy.2015.0116 10.1136/bmj.l1492 10.1503/cmaj.061730 10.1089/thy.2012.0532 10.1016/S0140-6736(18)32203-7 10.1111/cen.2005.62.issue-2 10.1007/s10654-007-9158-6 10.1016/S0140-6736(14)60571-7 10.1177/1179551419866196 10.1001/jamaoncol.2018.2706 10.1093/aje/kwm288 10.1016/S0140-6736(12)62205-3 |
| ContentType | Journal Article |
| Copyright | 2020. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Copyright 2020 Deng Y et al. . |
| Copyright_xml | – notice: 2020. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Copyright 2020 Deng Y et al. . |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S PHGZM PHGZT PIMPY PKEHL PQEST PQQKQ PQUKI PRINS 88C 8C1 M0T PJZUB PPXIY 7X8 5PM |
| DOI | 10.1001/jamanetworkopen.2020.8759 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni) ProQuest Central Premium ProQuest One Academic (New) ProQuest Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Healthcare Administration Database (Alumni) Public Health Database Healthcare Administration Database ProQuest Health & Medical Research Collection ProQuest One Health & Nursing MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) ProQuest One Health & Nursing ProQuest Health & Medical Research Collection Health & Medical Research Collection ProQuest Public Health ProQuest Health Management ProQuest Health Management (Alumni Edition) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic Publicly Available Content Database MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: Proquest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Public Health |
| DocumentTitleAlternate | Global Burden of Thyroid Cancer From 1990 to 2017 |
| EISSN | 2574-3805 2689-0186 |
| ExternalDocumentID | PMC7320301 32589231 10_1001_jamanetworkopen_2020_8759 |
| Genre | Journal Article |
| GroupedDBID | 0R~ 53G 7X7 8FI 8FJ AAYXX ABUWG ADBBV ADPDF AFKRA ALIPV ALMA_UNASSIGNED_HOLDINGS AMJDE BCNDV BENPR CCPQU CITATION EBS EMOBN FYUFA GROUPED_DOAJ H13 HMCUK M~E OK1 OVD OVEED PHGZM PHGZT PIMPY RAJ TEORI UKHRP W2D CGR CUY CVF ECM EIF NPM 3V. 7XB 8FK AZQEC DWQXO K9. PKEHL PQEST PQQKQ PQUKI PRINS 169 8C1 ABJNI FRP M0T PJZUB PPXIY 7X8 5PM |
| ID | FETCH-LOGICAL-a564t-23febfbc16714fd56d01f89a27088e94e25f60938aa841a45267abe7665cdd5b3 |
| IEDL.DBID | 7X7 |
| ISSN | 2574-3805 |
| IngestDate | Thu Aug 21 13:15:09 EDT 2025 Fri Jul 11 09:16:36 EDT 2025 Fri Jul 25 22:34:16 EDT 2025 Mon Jun 30 13:15:58 EDT 2025 Thu Apr 03 07:06:31 EDT 2025 Thu Apr 24 23:08:07 EDT 2025 Tue Jul 01 04:21:52 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Language | English |
| License | This is an open access article distributed under the terms of the CC-BY License. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-a564t-23febfbc16714fd56d01f89a27088e94e25f60938aa841a45267abe7665cdd5b3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://www.proquest.com/docview/2681065573?pq-origsite=%requestingapplication% |
| PMID | 32589231 |
| PQID | 2667921796 |
| PQPubID | 5319538 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7320301 proquest_miscellaneous_2418133998 proquest_journals_2681065573 proquest_journals_2667921796 pubmed_primary_32589231 crossref_citationtrail_10_1001_jamanetworkopen_2020_8759 crossref_primary_10_1001_jamanetworkopen_2020_8759 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2020-06-26 |
| PublicationDateYYYYMMDD | 2020-06-26 |
| PublicationDate_xml | – month: 06 year: 2020 text: 2020-06-26 day: 26 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Chicago |
| PublicationTitle | JAMA health forum |
| PublicationTitleAlternate | JAMA Netw Open |
| PublicationYear | 2020 |
| Publisher | American Medical Association |
| Publisher_xml | – name: American Medical Association |
| References | Ito (zoi200369r37) 2014; 24 Lee (zoi200369r38) 2014; 346 Stevens (zoi200369r19) 2016; 388 Brindel (zoi200369r26) 2008; 167 Vaccarella (zoi200369r29) 2015; 25 Shibuya (zoi200369r35) 2014; 383 Veiga (zoi200369r9) 2013; 23 Asban (zoi200369r21) 2019; 12 Ahn (zoi200369r14) 2015; 373 McLeod (zoi200369r36) 2013; 381 zoi200369r17 Keinan-Boker (zoi200369r6) 2016; 7 Etzioni (zoi200369r33) 2015; 108 Haugen (zoi200369r20) 2016; 26 Nilubol (zoi200369r22) 2013; 23 Reynolds (zoi200369r12) 2005; 62 Kent (zoi200369r3) 2007; 177 Kitahara (zoi200369r2) 2016; 12 Mayor (zoi200369r39) 2017; 356 Lubina (zoi200369r15) 2006; 16 Megwalu (zoi200369r27) 2017; 131 Uhry (zoi200369r10) 2007; 22 Cabanillas (zoi200369r4) 2016; 388 Lorenzoni (zoi200369r42) 2014; 384 Colonna (zoi200369r11) 2015; 39 Rahbari (zoi200369r28) 2010; 6 Pandeya (zoi200369r5) 2016; 84 The Lancet (zoi200369r32) 2017; 389 Bray (zoi200369r1) 2018; 68 Ahn (zoi200369r7) 2016; 26 Fitzmaurice (zoi200369r16) 2018; 4 GBD 2017 Causes of Death Collaborators (zoi200369r18) 2018; 392 Kilfoy (zoi200369r23) 2009; 18 Mazzaferri (zoi200369r24) 1994; 97 Park (zoi200369r31) 2013; 37 Morris (zoi200369r40) 2013; 23 Iacobucci (zoi200369r41) 2019; 364 Wang (zoi200369r8) 2015; 27 Smailyte (zoi200369r13) 2006; 6 Dal Maso (zoi200369r25) 2009; 20 Vaccarella (zoi200369r34) 2016; 375 Lee (zoi200369r30) 2014; 384 |
| References_xml | – volume: 84 start-page: 257 issue: 2 year: 2016 ident: zoi200369r5 article-title: Increasing thyroid cancer incidence in Queensland, Australia 1982-2008—true increase or overdiagnosis? publication-title: Clin Endocrinol (Oxf) doi: 10.1111/cen.2016.84.issue-2 – volume: 388 start-page: e19 issue: 10062 year: 2016 ident: zoi200369r19 article-title: Guidelines for Accurate and Transparent Health Estimates Reporting: the GATHER statement. publication-title: Lancet doi: 10.1016/S0140-6736(16)30388-9 – volume: 20 start-page: 75 issue: 1 year: 2009 ident: zoi200369r25 article-title: Risk factors for thyroid cancer: an epidemiological review focused on nutritional factors. publication-title: Cancer Causes Control doi: 10.1007/s10552-008-9219-5 – volume: 384 start-page: 1848 issue: 9957 year: 2014 ident: zoi200369r30 article-title: Overdiagnosis and screening for thyroid cancer in Korea. publication-title: Lancet doi: 10.1016/S0140-6736(14)62242-X – volume: 7 issue: 1 year: 2016 ident: zoi200369r6 article-title: Trends of thyroid cancer in Israel: 1980-2012. publication-title: Rambam Maimonides Med J doi: 10.5041/RMMJ.10228 – volume: 383 start-page: 1883 issue: 9932 year: 2014 ident: zoi200369r35 article-title: Time to reconsider thyroid cancer screening in Fukushima. publication-title: Lancet doi: 10.1016/S0140-6736(14)60909-0 – volume: 23 start-page: 885 issue: 7 year: 2013 ident: zoi200369r40 article-title: The increasing incidence of thyroid cancer: the influence of access to care. publication-title: Thyroid doi: 10.1089/thy.2013.0045 – volume: 6 start-page: 1771 issue: 11 year: 2010 ident: zoi200369r28 article-title: Thyroid cancer gender disparity. publication-title: Future Oncol doi: 10.2217/fon.10.127 – volume: 24 start-page: 27 issue: 1 year: 2014 ident: zoi200369r37 article-title: Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. publication-title: Thyroid doi: 10.1089/thy.2013.0367 – volume: 389 start-page: 1954 issue: 10083 year: 2017 ident: zoi200369r32 article-title: Thyroid cancer screening. publication-title: Lancet – volume: 16 start-page: 1033 issue: 10 year: 2006 ident: zoi200369r15 article-title: Time trends of incidence rates of thyroid cancer in Israel: what might explain the sharp increase. publication-title: Thyroid doi: 10.1089/thy.2006.16.1033 – volume: 12 start-page: 646 issue: 11 year: 2016 ident: zoi200369r2 article-title: The changing incidence of thyroid cancer. publication-title: Nat Rev Endocrinol doi: 10.1038/nrendo.2016.110 – volume: 97 start-page: 418 issue: 5 year: 1994 ident: zoi200369r24 article-title: Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. publication-title: Am J Med doi: 10.1016/0002-9343(94)90321-2 – volume: 6 start-page: 284 year: 2006 ident: zoi200369r13 article-title: Increasing thyroid cancer incidence in Lithuania in 1978-2003. publication-title: BMC Cancer doi: 10.1186/1471-2407-6-284 – volume: 18 start-page: 1092 issue: 4 year: 2009 ident: zoi200369r23 article-title: Gender is an age-specific effect modifier for papillary cancers of the thyroid gland. publication-title: Cancer Epidemiol Biomarkers Prev doi: 10.1158/1055-9965.EPI-08-0976 – volume: 108 issue: 3 year: 2015 ident: zoi200369r33 article-title: Recognizing the limitations of cancer overdiagnosis studies: a first step towards overcoming them. publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djv345 – volume: 23 start-page: 695 issue: 6 year: 2013 ident: zoi200369r22 article-title: Multivariate analysis of the relationship between male sex, disease-specific survival, and features of tumor aggressiveness in thyroid cancer of follicular cell origin. publication-title: Thyroid doi: 10.1089/thy.2012.0269 – volume: 373 start-page: 2389 issue: 24 year: 2015 ident: zoi200369r14 article-title: South Korea’s thyroid-cancer “epidemic”—turning the tide. publication-title: N Engl J Med doi: 10.1056/NEJMc1507622 – volume: 388 start-page: 2783 issue: 10061 year: 2016 ident: zoi200369r4 article-title: Thyroid cancer. publication-title: Lancet doi: 10.1016/S0140-6736(16)30172-6 – volume: 39 start-page: 511 issue: 4 year: 2015 ident: zoi200369r11 article-title: Recent trends in incidence, geographical distribution, and survival of papillary thyroid cancer in France. publication-title: Cancer Epidemiol doi: 10.1016/j.canep.2015.04.015 – volume: 37 start-page: 353 issue: 4 year: 2013 ident: zoi200369r31 article-title: Burden of cancer in Korea during 2000-2020. publication-title: Cancer Epidemiol doi: 10.1016/j.canep.2013.03.015 – volume: 375 start-page: 614 issue: 7 year: 2016 ident: zoi200369r34 article-title: Worldwide thyroid-cancer epidemic? the increasing impact of overdiagnosis. publication-title: N Engl J Med doi: 10.1056/NEJMp1604412 – volume: 27 start-page: NP223 issue: 2 year: 2015 ident: zoi200369r8 article-title: Increasing incidence of thyroid cancer in Shanghai, China, 1983-2007. publication-title: Asia Pac J Public Health doi: 10.1177/1010539512436874 – ident: zoi200369r17 – volume: 68 start-page: 394 issue: 6 year: 2018 ident: zoi200369r1 article-title: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. publication-title: CA Cancer J Clin doi: 10.3322/caac.v68.6 – volume: 26 start-page: 1535 issue: 11 year: 2016 ident: zoi200369r7 article-title: Thyroid cancer screening in South Korea increases detection of papillary cancers with no impact on other subtypes or thyroid cancer mortality. publication-title: Thyroid doi: 10.1089/thy.2016.0075 – volume: 346 start-page: 229 issue: 6206 year: 2014 ident: zoi200369r38 article-title: Is low fertility really a problem? population aging, dependency, and consumption. publication-title: Science doi: 10.1126/science.1250542 – volume: 26 start-page: 1 issue: 1 year: 2016 ident: zoi200369r20 article-title: 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. publication-title: Thyroid doi: 10.1089/thy.2015.0020 – volume: 356 start-page: j377 year: 2017 ident: zoi200369r39 article-title: UK children have “alarming gap” in health between rich and poor, report finds. publication-title: BMJ doi: 10.1136/bmj.j377 – volume: 131 start-page: 83 issue: 1 year: 2017 ident: zoi200369r27 article-title: Racial disparities in papillary thyroid microcarcinoma survival. publication-title: J Laryngol Otol doi: 10.1017/S0022215116009737 – volume: 25 start-page: 1127 issue: 10 year: 2015 ident: zoi200369r29 article-title: The impact of diagnostic changes on the rise in thyroid cancer incidence: a population-based study in selected high-resource countries. publication-title: Thyroid doi: 10.1089/thy.2015.0116 – volume: 364 start-page: l1492 year: 2019 ident: zoi200369r41 article-title: Life expectancy gap between rich and poor in England widens. publication-title: BMJ doi: 10.1136/bmj.l1492 – volume: 177 start-page: 1357 issue: 11 year: 2007 ident: zoi200369r3 article-title: Increased incidence of differentiated thyroid carcinoma and detection of subclinical disease. publication-title: CMAJ doi: 10.1503/cmaj.061730 – volume: 23 start-page: 748 issue: 6 year: 2013 ident: zoi200369r9 article-title: Thyroid cancer incidence patterns in Sao Paulo, Brazil, and the U.S. SEER program, 1997-2008. publication-title: Thyroid doi: 10.1089/thy.2012.0532 – volume: 392 start-page: 1736 issue: 10159 year: 2018 ident: zoi200369r18 article-title: Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. publication-title: Lancet doi: 10.1016/S0140-6736(18)32203-7 – volume: 62 start-page: 156 issue: 2 year: 2005 ident: zoi200369r12 article-title: Changing trends in incidence and mortality of thyroid cancer in Scotland. publication-title: Clin Endocrinol (Oxf) doi: 10.1111/cen.2005.62.issue-2 – volume: 22 start-page: 607 issue: 9 year: 2007 ident: zoi200369r10 article-title: Estimating infra-national and national thyroid cancer incidence in France from cancer registries data and national hospital discharge database. publication-title: Eur J Epidemiol doi: 10.1007/s10654-007-9158-6 – volume: 384 start-page: 83 issue: 9937 year: 2014 ident: zoi200369r42 article-title: Health-care expenditure and health policy in the USA versus other high-spending OECD countries. publication-title: Lancet doi: 10.1016/S0140-6736(14)60571-7 – volume: 12 year: 2019 ident: zoi200369r21 article-title: Gender and racial disparities in survival after surgery among papillary and patients with follicular thyroid cancer: a 45-year experience. publication-title: Clin Med Insights Endocrinol Diabetes doi: 10.1177/1179551419866196 – volume: 4 start-page: 1553 issue: 11 year: 2018 ident: zoi200369r16 article-title: Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the Global Burden of Disease Study. publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2018.2706 – volume: 167 start-page: 219 issue: 2 year: 2008 ident: zoi200369r26 article-title: Menstrual and reproductive factors in the risk of differentiated thyroid carcinoma in native women in French Polynesia: a population-based case-control study. publication-title: Am J Epidemiol doi: 10.1093/aje/kwm288 – volume: 381 start-page: 1046 issue: 9871 year: 2013 ident: zoi200369r36 article-title: Controversies in primary treatment of low-risk papillary thyroid cancer. publication-title: Lancet doi: 10.1016/S0140-6736(12)62205-3 |
| SSID | ssj0002013965 ssj0002511673 |
| Score | 2.5682592 |
| Snippet | Thyroid cancer is the most pervasive endocrine cancer worldwide. Studies examining the association between thyroid cancer and country, sex, age,... Importance Thyroid cancer is the most pervasive endocrine cancer worldwide. Studies examining the association between thyroid cancer and country, sex, age,... This cross-sectional study examines the worldwide temporal trends of thyroid cancer according to geographic location, sex, age, and socioeconomic index. |
| SourceID | pubmedcentral proquest pubmed crossref |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | e208759 |
| SubjectTerms | Adolescent Adult Age Aged Child Child, Preschool Cross-Sectional Studies Female Global Burden of Disease - statistics & numerical data Humans Incidence Male Middle Aged Neuroendocrine tumors Oncology Online Only Original Investigation Quality-Adjusted Life Years Thyroid cancer Thyroid Neoplasms - epidemiology Thyroid Neoplasms - mortality Trends Young Adult |
| Title | Global Burden of Thyroid Cancer From 1990 to 2017 |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/32589231 https://www.proquest.com/docview/2667921796 https://www.proquest.com/docview/2681065573 https://www.proquest.com/docview/2418133998 https://pubmed.ncbi.nlm.nih.gov/PMC7320301 |
| Volume | 3 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3daxQxEB-0BRFE_Ha1Hin4urq7-X4SPXoUwSLSwr0tySahhbpbr9cH_3tnLntLT1F82ZckbDKTj99MJr8BeNs5a1zSoex4qErhUyhd5WVpdVdxH7yKnh4nfzlRx2fi81IuR4fb9RhWud0TNxt1GDrykb9viDhLSan5h6sfJWWNotvVMYXGXdgn6jKa1XqpJx8LwWel-T04vE021Of4aspOhfZhU71DyG53j6U_sObvIZO3zqDFI3g4gkf2MWv7MdyJ_RN4kD1vLD8oegp1pvFn-YECGxI7Pf-5Gi4Cm5OGV2yxGr6zGs8Hth4Ynsz6GZwtjk7nx-WYGKF0Uol12fAUffIdDq4WKUgVqjoZ6xqNe0a0IjYyqcpy45wRtaMs4tr5qJWSXQjS8-ew1w99fAmskylEj0ayMkkk7T2KOFVo4xARnPWiALOVS9uNrOGUvOKyzXzHaD3sirQlkbYk0gKaqelVps74n0YHW-G342q6bhFEaIu2k1V_Kd5OjQIOp2JcJnT3gb8ZbrCOQCjDEY2ZAl5kVU6d4o00hHML0DtKnioQBfduSX9xvqHi1rwhm_LVv7v1Gu7TACnCrFEHsLde3cQ3iGXWfraZsPg183oG-5-OTr5-m238Ar8A0HT46A |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VIgESqngTWsCV4BhI_EwOqKoWVlv6OG2l3kIc22olSMp2K9Q_xW9kZr2JuiAQl57tJM487O-zPTMAb5q6LOpgXNoIl6XSBpfWmVVpaZpMWGe1txScfHikJ8fy84k6WYOffSwMXavs58TFRO26hvbI33NKnKWVMmLn_HtKVaPodLUvoRHNYt9f_UDKdvFh7yPq9y3n40_T0SRdVhVIa6XlPOUieBtsk2uTy-CUdlkeirLmBh3Ol9JzFTTy_KKuC5nXVILb1NYbrVXjnLIC33sLbkuBrkmR6aN82NMhuK6NuAPb15MbtfE-N1XDQj7Ks3dIEcrVZfAPbPv7Fc1ra974AWwswSrbjdb1ENZ8-wjux50-FgOYHkMeywawGBDBusCmp1ez7syxEVnUjI1n3TeW43rE5h1DJGCewPGNiOwprLdd658Da1Rw3iIp10WQwViLKg0ZcipKPFdamUDRy6VqllnKqVjG1yrmV0a2sirSikRakUgT4MOj5zFVx_88tNULv1p670WFoMWUyNVK_Zfm3hQT2B6a0S3prAU_011iH4nQSSD6KxJ4FlU5DEpwVRCuTsCsKHnoQCm_V1vas9NF6m8jOHHYF_8e1mu4O5keHlQHe0f7m3CPfpZut3G9Bevz2aV_iThqbl8tjJfBl5v2ll8O7jIs |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Global+Burden+of+Thyroid+Cancer+From+1990+to+2017&rft.jtitle=JAMA+network+open&rft.au=Deng%2C+YuJiao&rft.au=Li%2C+HongTao&rft.au=Wang%2C+Meng&rft.au=Li%2C+Na&rft.date=2020-06-26&rft.issn=2574-3805&rft.eissn=2574-3805&rft.volume=3&rft.issue=6&rft.spage=e208759&rft_id=info:doi/10.1001%2Fjamanetworkopen.2020.8759&rft.externalDBID=n%2Fa&rft.externalDocID=10_1001_jamanetworkopen_2020_8759 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2574-3805&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2574-3805&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2574-3805&client=summon |